Damon Runyon Researchers

Meet Our Scientists
Anusha Kalbasi, MD

Immune checkpoint inhibitors, a standard of care for metastatic melanoma, release the brakes on a patient's T cells, so they can attack a tumor. Some patients, however, relapse when resistance to treatment occurs. Dr. Kalbasi will lead a clinical trial to test a new immunotherapy treatment approach for patients with this deadly skin cancer, who did not respond to standard therapies. He will identify patients whose melanoma tumor cells express a protein called IL13Ra2. He will then collect the patient's immune T cells, engineer them to identify tumor cells that express the protein and reinfuse the T cells to kill tumor cells inside the patient. In contrast to immune checkpoint inhibitors that require regular intravenous doses, these engineered chimeric antigen receptor (CAR) T cells are a one-time treatment that theoretically protect the body for life. This clinical trial may also offer insights on how CAR T therapy overcomes tumor resistance mechanisms to treat patients with metastatic melanoma.

Project title: "IL13Ra2 Chimeric Antigen Receptor (CAR) T cells for metastatic melanoma"
Institution: University of California, Los Angeles
Award Program: Clinical Investigator
Sponsor(s) / Mentor(s): Antoni Ribas, MD, PhD, and Christine Brown, PhD
Cancer Type: Skin
Research Area: Immunotherapy